NASDAQ:AIMT - Aimmune Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $20.44 -0.04 (-0.20 %) (As of 05/22/2019 03:31 PM ET)Previous Close$20.48Today's Range$20.04 - $20.6352-Week Range$19.25 - $36.12Volume6,244 shsAverage Volume603,521 shsMarket Capitalization$1.28 billionP/E RatioN/ADividend YieldN/ABeta-0.2 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California. Receive AIMT News and Ratings via Email Sign-up to receive the latest news and ratings for AIMT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AIMT Previous Symbol CUSIPN/A CIK1631650 Webhttp://www.aimmune.com/ Phone650-614-5220Debt Debt-to-Equity Ratio0.19 Current Ratio7.65 Quick Ratio8.22Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.10 per share Price / Book4.99Profitability EPS (Most Recent Fiscal Year)($3.67) Net Income$-210,750,000.00 Net MarginsN/A Return on Equity-79.07% Return on Assets-66.43%Miscellaneous Employees228 Outstanding Shares62,492,000Market Cap$1.28 billion Next Earnings Date8/14/2019 (Estimated) OptionableOptionable Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions What is Aimmune Therapeutics' stock symbol? Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT." How were Aimmune Therapeutics' earnings last quarter? Aimmune Therapeutics Inc (NASDAQ:AIMT) released its quarterly earnings results on Thursday, February, 28th. The biotechnology company reported ($0.95) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.84) by $0.11. View Aimmune Therapeutics' Earnings History. When is Aimmune Therapeutics' next earnings date? Aimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for Aimmune Therapeutics. What price target have analysts set for AIMT? 6 analysts have issued 12 month target prices for Aimmune Therapeutics' stock. Their forecasts range from $30.00 to $80.00. On average, they expect Aimmune Therapeutics' share price to reach $50.50 in the next twelve months. This suggests a possible upside of 146.8% from the stock's current price. View Analyst Price Targets for Aimmune Therapeutics. What is the consensus analysts' recommendation for Aimmune Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aimmune Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aimmune Therapeutics. What are Wall Street analysts saying about Aimmune Therapeutics stock? Here are some recent quotes from research analysts about Aimmune Therapeutics stock: 1. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and 12-month PT of $45 per share of AIMT. Aimmune reported 1Q19 financial performance, ending the period with cash of $296M (potential access to an additional $130 million via KKR on US approval). Our model projects funding through several clin/reg milestones, including approval and initial commercialization of AR101 in the US & E.U. Based on recent diligence at AAAAI’19, we believe a market inefficiency exists for AR-101’s potential to be approved, experience robust early adoption, and transform the treatment of peanut allergy (PA)." (5/9/2019) 2. According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (5/8/2019) 3. Wedbush analysts commented, "SPRO announced that SPR720, an orally administered antimicrobial agent being developed for the treatment of non-tuberculous mycobacterial (NTM) infections, has been granted Product (QIDP) designation by the FDA. SPR720 is currently being evaluated in a Ph1 placebo-controlled clinical trial assessing safety, tolerability, and PK in healthy volunteers (data in 2H19). We’re encouraged by the significant progress at SPRO, especially in regards to: 1) FDA acceptance of an IND for SPR994, 2) meeting with FDA indicating that a single pivotal trial (ADAPT-PO) could support registration of SPR994, 3) nearterm initiation of the SPR994 Ph3 study which is posted on SAD/MAD data for SPR206 potentiator for gram-negative infections and SPR720 data in 2H19." (2/26/2019) Has Aimmune Therapeutics been receiving favorable news coverage? Media headlines about AIMT stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aimmune Therapeutics earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. Who are some of Aimmune Therapeutics' key competitors? Some companies that are related to Aimmune Therapeutics include Array Biopharma (ARRY), Horizon Therapeutics (HZNP), TESARO (TSRO), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), American Brivision (Holding) (ABVC), Evotec (EVTCY), Blueprint Medicines (BPMC), ACADIA Pharmaceuticals (ACAD), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Global Blood Therapeutics (GBT), FibroGen (FGEN) and Agios Pharmaceuticals (AGIO). What other stocks do shareholders of Aimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aimmune Therapeutics investors own include Hawkins (HWKN), CA (CA), Alibaba Group (BABA), Brainstorm Cell Therapeutics (BCLI), Micron Technology (MU), NVIDIA (NVDA), BlackRock (BLK), Endologix (ELGX), Clovis Oncology (CLVS) and Exelixis (EXEL). Who are Aimmune Therapeutics' key executives? Aimmune Therapeutics' management team includes the folowing people: Dr. Jayson Donald Alexander Dallas, Pres, CEO & Director (Age 51)Mr. Eric H. Bjerkholt, Chief Financial Officer (Age 59)Mr. Douglas T. Sheehy, Gen. Counsel & Sec. (Age 52)Dr. Stephen George Dilly, Special Advisor (Age 59)Dr. Daniel C. Adelman, Chief Medical Officer (Age 62) When did Aimmune Therapeutics IPO? (AIMT) raised $124 million in an initial public offering on Thursday, August 6th 2015. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO. Who are Aimmune Therapeutics' major shareholders? Aimmune Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.94%), FMR LLC (4.38%), Wellington Management Group LLP (2.87%), Eagle Asset Management Inc. (2.12%), Victory Capital Management Inc. (1.75%) and Emerald Advisers LLC (1.37%). Company insiders that own Aimmune Therapeutics stock include Bakker Juliet Tammenoms, Daniel C Md Adelman, Douglas T Sheehy, Eric Bjerkholt, Jayson Donald Alexander Dallas, Kathryn E Falberg, Mary M Rozenman, Patrick G Enright, Stephen George Dilly and Susan E Barrowcliffe. View Institutional Ownership Trends for Aimmune Therapeutics. Which major investors are selling Aimmune Therapeutics stock? AIMT stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, SG Americas Securities LLC, Wellington Management Group LLP, Citigroup Inc., Loomis Sayles & Co. L P, BlackRock Inc., Wells Fargo & Company MN and TD Asset Management Inc.. Company insiders that have sold Aimmune Therapeutics company stock in the last year include Douglas T Sheehy and Stephen George Dilly. View Insider Buying and Selling for Aimmune Therapeutics. Which major investors are buying Aimmune Therapeutics stock? AIMT stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Rice Hall James & Associates LLC, Rhenman & Partners Asset Management AB, Victory Capital Management Inc., Goldman Sachs Group Inc., Emerald Mutual Fund Advisers Trust, Botty Investors LLC and Emerald Advisers LLC. Company insiders that have bought Aimmune Therapeutics stock in the last two years include Bakker Juliet Tammenoms, Eric Bjerkholt, Jayson Donald Alexander Dallas, Kathryn E Falberg and Patrick G Enright. View Insider Buying and Selling for Aimmune Therapeutics. How do I buy shares of Aimmune Therapeutics? Shares of AIMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Aimmune Therapeutics' stock price today? One share of AIMT stock can currently be purchased for approximately $20.46. How big of a company is Aimmune Therapeutics? Aimmune Therapeutics has a market capitalization of $1.28 billion. The biotechnology company earns $-210,750,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis. Aimmune Therapeutics employs 228 workers across the globe. What is Aimmune Therapeutics' official website? The official website for Aimmune Therapeutics is http://www.aimmune.com/. How can I contact Aimmune Therapeutics? Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected] MarketBeat Community Rating for Aimmune Therapeutics (NASDAQ AIMT)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 341 (Vote Outperform)Underperform Votes: 232 (Vote Underperform)Total Votes: 573MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote "Outperform" if you believe AIMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AIMT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: What Are Cryptocurrencies? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.